Alan H. Bryce, MD

City of Hope

Phoenix, Arizona

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope. Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Disclosures:

Dr. Bryce has the following disclosures:
Consulting Fees: Astellas, Bayer, Novartis

Talks by Alan H. Bryce, MD

The DECIPHER Marker Can Predict Chemotherapy

Posted by Alan H. Bryce, MD | Jan 2018

Alan H. Bryce, MD makes the pro side of the argument that the DECIPHER marker is an effective tool for predicting a patient’s response to chemotherapy. He also summarizes the ongoing trials and research regarding this specific biomarker. This is a counter argument to Robert Abouassaly’s lecture, “Can The DECIPHER Marker Can Predict Chemotherapy?”

Alan H. Bryce, MD

City of Hope

Phoenix, Arizona

Talks by Alan H. Bryce, MD

The DECIPHER Marker Can Predict Chemotherapy

Join the GRU Community

You have Successfully Subscribed!